Skip to main content

Table 2 DERP SRs with changes in findings based on dossier evidence

From: A study of the value of requesting information from drug manufacturers for systematic reviews; 9 years of experience from the drug effectiveness review project

DERP SR N and type of evidence* N unpublished Fills gaps? (N) Contradicts other evidence?
Atypical antipsychotics
update 2
1 unique study 0 No No
Atypical antipsychotics
update 3
23 unique study
3 supplemental data
20
3
Yes (19)
Yes (3)
No, included in meta-analyses
Atypical antipsychotics
update 4
2 unique study
1 supplemental data
1
0
Yes (2)
Yes (1)
NA
ADHD update 4 1 unique study No Yes (1) NA
Asthma/COPD 5 unique study
1 supplemental data
2
0
Yes (4)
Yes (1)
No, included in meta-analysis
Combination products 1 unique study 0 Yes (1) NA
Diabetes drugs 2 unique study 0 Yes (2) NA
Hepatitis C original 2 unique study 1 Yes (2) NA
Hepatitis C update 1 3 unique study 1 Yes (3) NA
Long-acting insulins 4 unique study
2 supplemental data
0
0
Yes (3)
Yes (2)
Yes, findings in offspring of women using insulin during pregnancy contradict one other study found.
Multiple sclerosis update 2 1 unique study 0 No Yes, contradicted findings of studies with longer duration (favored manufacturers drug in shorter duration, no difference with longer duration)
Neuropathic pain 1 unique study 0 Yes (1) NA
Proton pump inhibitors Update 5 6 unique study 0 Yes (6) NA
Topical calcineurin inhibitors 3 unique study
1 supplemental data
1
0
Yes (2)
Yes (1)
NA
Triptans update 4 1 supplemental data 1 Yes (1) NA
  1. *Unique = new unique study, Supplemental = data that supplements a previously identified unique study, NA, not applicable